Hoping to bag the ResMed dividend? You better be quick!

Is a healthy dividend on the way?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It won't be long before the next Resmed CDI (ASX: RMD) dividend is on its way to shareholders. If investors want to gain access to the payout, they'll need to be quick because it's nearly deadline day!

The ex-dividend date is one of the most important dates when it comes to dividend investing. Investors need to own shares before the ex-dividend date to gain entitlement to the upcoming payment. If investors buy on the ex-dividend date (or afterwards), they'll miss out.

A businessman holding a butterfly net looks around hoping to snare a good ASX share investment

Image source: Getty Images

Resmed ex-dividend date

The ex-dividend date for the imminent quarterly payment is on Wednesday, 7 February. That means, to ensure entitlement to this upcoming dividend, investors will need to own Resmed shares by the end of trading tomorrow, 6 February.

The ASX healthcare share is planning to pay this dividend of US 4.8 cents per share on 14 March 2024.

At the current foreign exchange rate, that would translate into a payment of AU 7.3 cents per share. Resmed will provide further details about the size of the dividend in Australian dollar terms on Friday, 9 February.

Profitability performance

Resmed recently announced its FY24 second quarter performance for the three months to 31 December 2023.

It reported that revenue increased by 12% to $1.2 billion, the underlying gross profit margin improved 10 basis points to 56.9%, the underlying (non-GAAP) operating profit improved 20%, and it made an operating cash flow of $272.8 million.

You can read more about that update from our coverage of the quarter.

Management said strong growth in patient flow over the past several quarters had "supported ongoing device growth" and added to replenishment programs for "sustained mask and accessories growth". It was also launching its latest generation platform, AirSense 11, into new markets and geographies.

Resmed share price snapshot

The Resmed share price has fallen more than 8% over the past year.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Broker sees 26% upside in ASX healthcare share behind Chemist Warehouse

Morgans has just upgraded its rating on this ASX healthcare stock due to ongoing share price weakness.

Read more »

Woman using a pen on a digital stock market chart in an office.
Healthcare Shares

Why this ASX healthcare stock is surging while the market sinks on Middle East fears

Avita shares surge as a US government contract boosts sentiment again

Read more »

A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer
Healthcare Shares

Should you buy Telix shares after its big US news?

Is this milestone a reason to invest? Let's find out.

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Up 31% in a month, why are Telix shares lifting off again on Friday?

ASX investors are piling into Telix shares today. But why?

Read more »

Doctor checking patient's spine x-ray image.
Healthcare Shares

Where is the value amongst ASX healthcare shares?

These three stocks are worth monitoring.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Telix Pharmaceuticals: FDA accepts Pixclara NDA

The FDA has accepted Telix's Pixclara NDA for imaging brain cancer.

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Bell Potter says this ASX healthcare stock could rise nearly 200%

The positive announcement has reinforced the broker's recommendation.

Read more »

A man rests his chin in his hands, pondering what is the answer?
Healthcare Shares

CSL shares: 3 reasons to buy and 3 reasons to sell

CSL shares have tumbled again.

Read more »